Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

Bookmark and Share
Published: 30 May 2015
Views: 1689
Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada

Dr Sehn presents at a press conference at ASCO 2015 about a phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy significantly delays progression of indolent non-Hodgkin lymphoma (NHL).

Read the news article for more.